Ultragenyx Pharmaceutical Inc. (RARE)

Last Closing Price: 17.22 (2026-11-19)

Company Description

Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $673.00M
Net Income (Most Recent Fiscal Year) $-575.00M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) 2.48
Price to Book Ratio (Most Recent Quarterly Book Value per Share) --
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) -72.60%
Net Margin (Trailing 12 Months) -71.78%
Return on Equity (Trailing 12 Months) --
Return on Assets (Trailing 12 Months) -39.70%
Current Ratio (Most Recent Fiscal Quarter) 1.40
Quick Ratio (Most Recent Fiscal Quarter) 1.25
Debt to Common Equity (Most Recent Fiscal Quarter) --
Inventory Turnover (Trailing 12 Months) 2.22
Book Value per Share (Most Recent Fiscal Quarter) $-3.69
Earnings per Share (Most Recent Fiscal Quarter) $-1.16
Earnings per Share (Most Recent Fiscal Year) $-5.83
Diluted Earnings per Share (Trailing 12 Months) $-5.19
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 101.92M
Free Float 96.62M
Market Capitalization $1.81B
Average Volume (Last 20 Days) 3.86M
Beta (Past 60 Months) 0.37
Percentage Held By Insiders (Latest Annual Proxy Report) 5.20%
Percentage Held By Institutions (Latest 13F Reports) 97.67%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%